Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy

doi:10.4252/wjsc.v9.i3.45

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15059)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

742

WORD

414

HTML

7715

Figures (1-6)

558

Sum=9429

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

1002

Download

1880

Sum=2882

Publishing Process of This Article

Item

Count

Browse

1251

Download

1496

Sum=2747

Mar 26, 2017 (publication date) through Mar 25, 2026

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Stem Cells. Mar 26, 2017; 9(3): 45-67
Published online Mar 26, 2017. doi: 10.4252/wjsc.v9.i3.45

Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy

Jorge Zorzopulos, Steven M Opal, Andrés Hernando-Insúa, Juan M Rodriguez, Fernanda Elías, Juan Fló, Ricardo A López, Norma A Chasseing, Victoria A Lux-Lantos, Maria F Coronel, Raul Franco, Alejandro D Montaner, David L Horn

Jorge Zorzopulos, Juan Fló, Ricardo A López, Raul Franco, Immunotech S.A., Ciudad de Buenos Aires C1440FFX, Argentina

Steven M Opal, Infectious Disease Division, Memorial Hospital of Rhode Island and Alpert Medical School, Providence, RI 02905, United States

Andrés Hernando-Insúa, Juan M Rodriguez, Fernanda Elías, Alejandro D Montaner, Fundación Pablo Cassara, Ciudad Autonoma de Buenos Aires C1440FFX, Argentina

Norma A Chasseing, Maria F Coronel, Vicoria A Lux-Lantos, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Ciudad Autónoma de Buenos Aires C1428ADN, Argentina

Alejandro D Montaner, Instituto de Ciencia y Tecnologıa “Dr. Cesar Milstein”, Fundación Pablo Cassará, Ciudad Autonoma de Buenos Aires C1440FFX, Argentina

David L Horn, David Horn LLC, Doylestown, PA 18902, United States

Author contributions: All authors contributed equally to this paper in conception and design of definite studies, and in analysis, drafting, critical revision, editing, and providing final approval of the version to be published; Zorzopulos J reviewed the literature and wrote the paper.

Conflict-of-interest statement: López RA and Zorzopulos J are shareholders of Immunotech, the company that provided funding for several of the studies partially described in this review; Horn DL is the owner and CEO of David Horn, LLC, which owns all the IMT504 patents [Patents numbers: EP1511845B1. Immunostimulatory oligonucleotides and uses thereof. International application number: PCT/EP2003/005691. International publication number: WO2003/101375. US7943316(B2)]. There are no further patents, products in development, or marketed products to declare. These statements do not alter the authors’ adherence to all the BPG policies on sharing data and material.

Correspondence to: Alejandro D Montaner, PhD, Instituto de Ciencia y Tecnologıa “Dr. Cesar Milstein”, Fundación Pablo Cassará, 2453 Saladillo Street, Ciudad Autonoma de Buenos Aires C1440FFX, Argentina. amontaner@fundacioncassara.org.ar

Telephone: +54-11-41054126-2102

Received: July 12, 2016
Peer-review started: July 13, 2016
First decision: September 2, 2016
Revised: October 28, 2016
Accepted: December 16, 2016
Article in press: December 19, 2016
Published online: March 26, 2017
Processing time: 256 Days and 22.8 Hours

Core Tip

Core tip: Mesenchymal stem cell (MSC) transplant has been demonstrated to be an effective therapy in preclinical studies evaluating a vast diversity of inflammatory conditions. However, in clinical trials of transplanted MSCs, the expectations of great medical benefit have not yet been fulfilled. In this regard, IMT504, the prototype of a major class of immunomodulatory oligonucleotides, induces in vivo expansion of MSCs, resulting in a marked improvement in preclinical models of neuropathic pain, osteoporosis, diabetes and sepsis. IMT504 is easily manufactured and has an excellent preclinical safety record. Further clinical investigation is necessary to demonstrate the utility of IMT504 for resolution of inflammation and regeneration in a broad array of human diseases that are likely to benefit from an immunoprotective/immunoregenerative therapy.